Literature DB >> 8429039

Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9.

K K Hamilton1, J Zhao, P J Sims.   

Abstract

We have previously observed enhanced binding of HDL and apolipoproteins A-I and A-II to human endothelial cells exposed to activated complement. Induction of these binding sites required complement activation through C9, suggesting a specific role for the C9 component of the C5b-9 complex. We now report that specific and saturable binding sites for apoA-I and -A-II are expressed by C9 polymers (polyC9), whereas little binding was observed to native monomeric C9. These data suggested an interaction of the apoproteins with a site(s) which is exposed only upon C9 polymerization, and also suggested that binding of the apoproteins to this new site might interfere with assembly of C9 into the polyC9 tubule and insertion into the cell membrane. ApoA-I was found to inhibit zinc-catalyzed polymerization of C9 in a concentration-dependent fashion. Formation of SDS-resistant C9 polymers was completely inhibited at apoA-I or -A-II concentrations > or = 5 microM. ApoA-I also produced a concentration-dependent inhibition of C9 incorporation into C5b-9 complexes on endothelial cells, which was accompanied by a corresponding decrease in SDS-resistant C9 polymers associated with the cell membrane. In summary, the ability of the HDL apoproteins A-I and A-II to interact with an activation-dependent conformer(s) of the C9 component of the C5b-9 complex appears to explain the expression of HDL binding sites on endothelial cells exposed to complement. These apoproteins are also inhibitors of C9 polymerization, which may underlie the protective effect of HDL for blood cells exposed to activated complement.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429039

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

3.  HDL proteomics: pot of gold or Pandora's box?

Authors:  Muredach P Reilly; Alan R Tall
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

4.  The HDL proteome: a marker--and perhaps mediator--of coronary artery disease.

Authors:  Jay W Heinecke
Journal:  J Lipid Res       Date:  2008-12-05       Impact factor: 5.922

Review 5.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

6.  Lipid-binding and antimicrobial properties of synthetic peptides of bovine apolipoprotein A-II.

Authors:  M Motizuki; T Itoh; T Satoh; S Yokota; M Yamada; S Shimamura; T Samejima; K Tsurugi
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

7.  Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia.

Authors:  Andrew N Hoofnagle; Mingyuan Wu; Albina K Gosmanova; Jessica O Becker; Ellen M Wijsman; John D Brunzell; Steven E Kahn; Robert H Knopp; Timothy J Lyons; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09-16       Impact factor: 8.311

8.  Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome.

Authors:  Elena Burillo; Rocío Mateo-Gallego; Ana Cenarro; Sarah Fiddyment; Ana M Bea; Inmaculada Jorge; Jesús Vázquez; Fernando Civeira
Journal:  Lipids Health Dis       Date:  2012-09-16       Impact factor: 3.876

9.  High-density lipoproteins and the immune system.

Authors:  Hidesuke Kaji
Journal:  J Lipids       Date:  2013-01-30

Review 10.  Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.

Authors:  Yamir Islam; Andrew G Leach; Jayden Smith; Stefano Pluchino; Christopher R Coxon; Muttuswamy Sivakumaran; James Downing; Amos A Fatokun; Meritxell Teixidò; Touraj Ehtezazi
Journal:  Adv Sci (Weinh)       Date:  2021-03-15       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.